• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacology before, during and after percutaneous coronary intervention.

作者信息

Zaman Azfar G, Aleem Qaiser

机构信息

Cardiology, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK

Cardiology, James Cook University Hospital, Middlesborough, UK.

出版信息

Heart. 2020 Nov 4;107(7):585-92. doi: 10.1136/heartjnl-2019-315090.

DOI:10.1136/heartjnl-2019-315090
PMID:33148548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7958112/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e5/7958112/d180fbea44e2/heartjnl-2019-315090f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e5/7958112/d180fbea44e2/heartjnl-2019-315090f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e5/7958112/d180fbea44e2/heartjnl-2019-315090f01.jpg

相似文献

1
Pharmacology before, during and after percutaneous coronary intervention.经皮冠状动脉介入治疗前、治疗期间及治疗后的药理学
Heart. 2020 Nov 4;107(7):585-92. doi: 10.1136/heartjnl-2019-315090.
2
Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.在因支架内血栓形成抬高型急性心肌梗死接受直接冠状动脉介入治疗的患者中使用比伐卢定的当前发生率及临床结果。
Coron Artery Dis. 2007 Mar;18(2):141-8. doi: 10.1097/MCA.0b013e328010a4b2.
3
Assessment of cardiac parameters after the administration of nicorandil before primary percutaneous coronary intervention.评估尼可地尔给药对直接经皮冠状动脉介入治疗后心脏参数的影响。
J Pak Med Assoc. 2024 May;74(5):917-921. doi: 10.47391/JPMA.9981.
4
Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后早期支架血栓形成与死亡率：2 项随机临床试验的患者水平分析。
Circ Cardiovasc Interv. 2016 May;9(5):e003272. doi: 10.1161/CIRCINTERVENTIONS.115.003272.
5
Combined analysis of the safety of intra-coronary drug delivery during primary percutaneous coronary intervention for acute myocardial infarction: A study of three clinical trials.急性心肌梗死直接经皮冠状动脉介入治疗期间冠状动脉内给药安全性的联合分析：三项临床试验研究
JRSM Cardiovasc Dis. 2017 Aug 16;6:2048004017725988. doi: 10.1177/2048004017725988. eCollection 2017 Jan-Dec.
6
Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.坎格雷洛：药理学、临床数据及在经皮冠状动脉介入治疗中的作用
Interv Cardiol Clin. 2017 Jan;6(1):39-47. doi: 10.1016/j.iccl.2016.08.012.
7
Contributors to the Growth of Same Day Discharge After Elective Percutaneous Coronary Intervention.择期经皮冠状动脉介入治疗后当天出院增长的促成因素。
Circ Cardiovasc Interv. 2020 Mar;13(3):e008458. doi: 10.1161/CIRCINTERVENTIONS.119.008458. Epub 2020 Mar 10.
8
Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients.依替巴肽在ST段抬高型心肌梗死的直接经皮冠状动脉介入治疗中使用时，与显著的成本节约相关，且临床结果与阿昔单抗相似：一项对3863例患者的观察性队列研究。
JRSM Cardiovasc Dis. 2017 Oct 5;6:2048004017734431. doi: 10.1177/2048004017734431. eCollection 2017 Jan-Dec.
9
Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention: A systematic review and meta-analysis.经皮冠状动脉介入治疗后冠心病患者临床结局的性别差异：一项系统评价和荟萃分析。
Medicine (Baltimore). 2018 Jul;97(30):e11644. doi: 10.1097/MD.0000000000011644.
10
Impact of left ventricular ejection fraction and medication adherence on major adverse cardiac events during the first year after successful primary percutaneous coronary interventions.成功进行直接经皮冠状动脉介入治疗后第一年，左心室射血分数和药物依从性对主要不良心脏事件的影响。
J Clin Nurs. 2016 Apr;25(7-8):1101-11. doi: 10.1111/jocn.13109. Epub 2015 Dec 27.

本文引用的文献

1
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.高出血风险患者中使用聚合物基或无聚合物支架。
N Engl J Med. 2020 Mar 26;382(13):1208-1218. doi: 10.1056/NEJMoa1910021. Epub 2020 Feb 12.
2
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.替格瑞洛联合或不联合阿司匹林用于 PCI 术后高危患者。
N Engl J Med. 2019 Nov 21;381(21):2032-2042. doi: 10.1056/NEJMoa1908419. Epub 2019 Sep 26.
3
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
依度沙班与维生素 K 拮抗剂在房颤患者成功经皮冠状动脉介入治疗后抗栓治疗方案的比较（ENTRUST-AF PCI）：一项随机、开放标签、3b 期临床试验。
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
4
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.替格瑞洛在既往经皮冠状动脉介入治疗史的糖尿病合并稳定型冠状动脉疾病患者中的应用（THEMIS-PCI）：一项 3 期、安慰剂对照、随机临床试验。
Lancet. 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1.
5
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.替格瑞洛在稳定型冠心病合并糖尿病患者中的应用。
N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1.
6
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.心房颤动急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗血栓治疗。
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
7
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
8
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗血栓治疗：北美视角-2018 年更新。
Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
9
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.替格瑞洛联合阿司匹林治疗 1 个月，随后替格瑞洛单药治疗 23 个月，与阿司匹林联合氯吡格雷或替格瑞洛治疗 12 个月，随后药物洗脱支架植入后阿司匹林单药治疗 12 个月：一项多中心、开放标签、随机优效性试验。
Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27.
10
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).2018 年欧洲共识文件：急性冠状动脉综合征和/或经皮心血管介入治疗的心房颤动患者抗栓治疗管理：欧洲心律协会（EHRA）、欧洲心脏病学会血栓工作组、欧洲经皮心血管介入协会（EAPCI）和欧洲急性心脏护理协会（ACCA）的联合共识文件，得到了心律学会（HRS）、亚太心律学会（APHRS）、拉丁美洲心律学会（LAHRS）和南非心脏心律失常学会（CASSA）的认可。
Europace. 2019 Feb 1;21(2):192-193. doi: 10.1093/europace/euy174.